JP2022547552A5 - - Google Patents
Info
- Publication number
- JP2022547552A5 JP2022547552A5 JP2022515826A JP2022515826A JP2022547552A5 JP 2022547552 A5 JP2022547552 A5 JP 2022547552A5 JP 2022515826 A JP2022515826 A JP 2022515826A JP 2022515826 A JP2022515826 A JP 2022515826A JP 2022547552 A5 JP2022547552 A5 JP 2022547552A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antigen
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962898896P | 2019-09-11 | 2019-09-11 | |
| US62/898,896 | 2019-09-11 | ||
| US202062985808P | 2020-03-05 | 2020-03-05 | |
| US62/985,808 | 2020-03-05 | ||
| PCT/US2020/050090 WO2021050656A1 (en) | 2019-09-11 | 2020-09-10 | Compositions and methods comprising prostate stem cell antigen (psca) chimeric antigen receptors (cars) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022547552A JP2022547552A (ja) | 2022-11-14 |
| JP2022547552A5 true JP2022547552A5 (enExample) | 2023-09-14 |
| JP7682859B2 JP7682859B2 (ja) | 2025-05-26 |
Family
ID=74849499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022515826A Active JP7682859B2 (ja) | 2019-09-11 | 2020-09-10 | 前立腺幹細胞抗原（ｐｓｃａ）キメラ抗原受容体（ｃａｒ）を含む組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11766453B2 (enExample) |
| EP (1) | EP4028414A4 (enExample) |
| JP (1) | JP7682859B2 (enExample) |
| CN (1) | CN114729059A (enExample) |
| AU (1) | AU2020347171A1 (enExample) |
| WO (1) | WO2021050656A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117843812A (zh) * | 2020-05-22 | 2024-04-09 | 重庆精准生物技术有限公司 | 逆转肿瘤微环境的融合蛋白及其应用 |
| CA3231670A1 (en) * | 2021-09-10 | 2023-03-16 | Kite Pharma, Inc. | Alternative generation of allogeneic human t cells |
| EP4479068A4 (en) * | 2022-02-18 | 2026-01-07 | Univ California | ENHANCED MULTIPLICATION AND FUNCTION OF PRIMARY HUMAN NK CELLS BY A CHIMERICAL CYTOKINE RECEPTOR |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| TW202442689A (zh) | 2023-03-03 | 2024-11-01 | 美商亞森諾生物科學公司 | 靶向ｐｓｍａ及ｃａ９之系統 |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025235801A1 (en) | 2024-05-08 | 2025-11-13 | City Of Hope | Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2386366T3 (es) * | 2005-02-18 | 2012-08-17 | Medarex, Inc. | Anticuerpo monoclonal humano contra el antígeno de membrana específico de la próstata (PSMA) |
| US8940298B2 (en) * | 2007-09-04 | 2015-01-27 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection |
| KR101837053B1 (ko) * | 2008-10-01 | 2018-03-12 | 암젠 리서치 (뮌헨) 게엠베하 | 종간 특이적 ＰＳＣＡｘＣＤ３, ＣＤ19ｘＣＤ3, ｃ-ＭＥＴｘＣＤ3, 엔도시알린ｘＣＤ3, ＥｐＣＡＭｘＣＤ3, ＩＧＦ-1ＲｘＣＤ3 또는 ＦＡＰαｘＣＤ3 이중특이적 단일쇄 항체 |
| CA3285826A1 (en) * | 2012-02-22 | 2026-03-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| KR20150029714A (ko) * | 2012-07-13 | 2015-03-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강 |
| WO2014059173A2 (en) * | 2012-10-10 | 2014-04-17 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
| EP2970372B1 (en) * | 2013-03-15 | 2020-09-30 | Celgene Corporation | Modified t lymphocytes |
| CN122399016A (zh) | 2014-03-15 | 2026-07-17 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| PL3212225T3 (pl) * | 2014-10-31 | 2026-03-30 | The Trustees Of The University Of Pennsylvania | Sposoby i kompozycje zmodyfikowanych limfocytów t |
| EP3747462A1 (en) * | 2015-10-06 | 2020-12-09 | City of Hope | Chimeric antigen receptors targeted to psca |
| CN117534764A (zh) | 2016-06-06 | 2024-02-09 | 阿布泽纳(英国)有限公司 | 抗体、其用途及其缀合物 |
| GB201614162D0 (en) | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
| CN108395480A (zh) | 2017-02-08 | 2018-08-14 | 广州百尼夫生物科技有限公司 | 嵌合抗原受体及其基因和重组表达载体、carher2-nkt细胞及其制备方法和应用 |
| SG11201908784TA (en) * | 2017-03-27 | 2019-10-30 | Hoffmann La Roche | Improved antigen binding receptor formats |
| US10934336B2 (en) * | 2017-04-13 | 2021-03-02 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy |
| US11738047B2 (en) * | 2017-12-12 | 2023-08-29 | The Trustees Of The University Of Pennsylvania | Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof |
| CN109593726A (zh) * | 2018-12-26 | 2019-04-09 | 重庆精准生物技术有限公司 | 增强car-t细胞归巢到实体肿瘤组织能力的试剂及其应用 |
-
2020
- 2020-09-10 CN CN202080078234.1A patent/CN114729059A/zh active Pending
- 2020-09-10 US US17/017,238 patent/US11766453B2/en active Active
- 2020-09-10 AU AU2020347171A patent/AU2020347171A1/en not_active Abandoned
- 2020-09-10 JP JP2022515826A patent/JP7682859B2/ja active Active
- 2020-09-10 WO PCT/US2020/050090 patent/WO2021050656A1/en not_active Ceased
- 2020-09-10 EP EP20863540.9A patent/EP4028414A4/en active Pending
-
2023
- 2023-09-08 US US18/463,630 patent/US20240041921A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107847574B (zh) | Pd-1结合分子和其使用方法 | |
| JP7796079B2 (ja) | モジュラー四価二重特異性抗体プラットフォーム | |
| JP2022548778A5 (enExample) | ||
| JP6702893B2 (ja) | 多重特異的抗原結合タンパク質 | |
| JP6378087B2 (ja) | Ｂｃｍａおよびｃｄ３に対する結合分子 | |
| KR20200079511A (ko) | Cd47 항원-결합 분자 | |
| JP2018503401A5 (enExample) | ||
| AU2020267504A1 (en) | Materials and methods for modulating T cell mediated immunity | |
| KR20110066960A (ko) | 종간 특이적 ＰＳＣＡｘＣＤ３, ＣＤ19ｘＣＤ3, ｃ-ＭＥＴｘＣＤ3, 엔도시알린ｘＣＤ3, ＥｐＣＡＭｘＣＤ3, ＩＧＦ-1ＲｘＣＤ3 또는 ＦＡＰαｘＣＤ3 이중특이적 단일쇄 항체 | |
| JP2022542559A5 (enExample) | ||
| WO2016122701A1 (en) | Anti-dr5 antibodies and molecules comprising dr5-binding domains thereof | |
| IL298449A (en) | Improved antigen binding receptors | |
| AU2018315432A1 (en) | CD96-binding agents as immunomodulators | |
| CA3175134A1 (en) | Materials and methods for modulating delta chain mediated immunity | |
| WO2022056197A9 (en) | Immune targeting molecules and uses thereof | |
| CN117355540A (zh) | 抗cd137抗体和使用方法 | |
| CA3227854A1 (en) | Novel anti-sirpa antibodies | |
| JP2025504795A (ja) | 抗体及びその用途 | |
| TWI917473B (zh) | Bcma/taci抗原結合分子 | |
| CN119213023A (zh) | Ilt3和cd3结合剂以及其使用方法 | |
| JP2024105603A (ja) | ＣＡＲライブラリおよびｓｃＦｖの製造方法 | |
| EP4326774A1 (en) | Kidney-glomerular targeted immunotherapy | |
| WO2025103456A1 (en) | Gprc5d-binding moieties, chimeric antigen receptors and uses thereof | |
| US20250270318A1 (en) | Multispecific antibodies and uses thereof | |
| RU2805648C2 (ru) | Биспецифические связывающие молекулы, способные связывать cd137 и опухолевые антигены, и варианты их применения |